Biopharmaceutical company Fate Therapeutics, Inc said the US Patent and Trademark Office issued a patent covering “the use of prostaglandins as viral transduction enhancers for the genetic modification of CD34+ hematopoietic cells.”
The patent, which expires in 2029, is owned by the Indiana University Research and Technology Corporation and is licensed exclusively to Fate Therapeutics in all fields.
Fate Therapeutics CEO Scott Wolchko said: “The use of small molecules in the manufacture of cell therapies is proving to be a key component for promoting efficacy.
“Studies have demonstrated that ex vivo small molecule modulation can enhance the viral transduction, engraftment and survival of CD34+ cells and the persistence, proliferation and anti-tumor activity of NK cells and T cells.
“Using prostaglandins to improve vector copy number and percentage of hematopoietic cells transduced in the manufacture of gene therapies is a promising approach to help enable the development of curative treatments for a range of severe genetic disorders.”